Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07586449

A Prospective Observational Study of Senaparib in the Treatment of Epithelial Ovarian Cancer

Sponsor: Zhejiang Cancer Hospital

View on ClinicalTrials.gov

Summary

Ovarian cancer is one of the most fatal malignant tumors that threaten women's health. The incidence rate is the third place among the female reproductive system malignant tumors, and the mortality rate ranks the first in gynecologic malignancies, the majority of patients have advanced diseases at the time of diagnosis. This observational study is to evaluate the safety and efficacy of senaparib in ovarian cancer patients under real conditions, especially in various subgroups of ovarian cancer patients, in order to provide information about treatment modes for ovarian cancer patients in real-world diagnosis and treatment。

Official title: Evaluation of Safety and Effectiveness of Senaparib in Epithelial Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer: A Prospective Observational Real-World Study

Key Details

Gender

FEMALE

Age Range

18 Years - Any

Study Type

OBSERVATIONAL

Enrollment

500

Start Date

2026-06-10

Completion Date

2030-12-31

Last Updated

2026-05-14

Healthy Volunteers

No

Interventions

DRUG

Senaparib capsules(20mg)

senaparib monotherapy or combination therapy

Locations (1)

Zhejiang Cancer Hospital

Hangzhou, Zhejiang, China